Orgenesis Inc (ORGS) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket
 
Orgenesis Inc   (ORGS)
 

Orgenesis Inc Growth Comparisons

Select each growth Category to receive further Information





ORGS Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q4 MRQ) 82.42 % 12.12 % 7.69 % 5.68 %
Q / Q Revenue Growth (Q4 MRQ) -13.26 % 3.94 % 3.27 % 2.63 %
Y / Y Revenue Growth (for 12 months ending Q4 TTM) 95.28 % 7.48 % 5.74 % %
Sequential Revenue Growth (for 12 months ending Q4 TTM) 15.13 % 4.08 % 2.39 % 1.74 %
Revenue 5 Year Average Growth -68.27 % 14.14 % 10.98 % 7.76 %


ORGS's Growth Comparisons in IV. Quarter 2024




Orgenesis Inc reported top-line of $ 0 millions in the fourth quarter 2024, compare to $ 0 millions in the same quarter a year ago. Revenues in the Major Pharmaceutical Preparations industry grew by 12.12%, while the top-line in the Healthcare sector increased by 7.69%, and overall market improved by 5.68% from the fourth quarter 2023.

Sequentially company's Revenue fell by -13.26% from the third quarter results. . Looking into annual growth, sales grew by -68.27% on average in last five years, while S & P 500's including only Businesses with the fourth quarter 2024 earnings reports, average yearly sales growth is 7.76%.


Growth Rates of ORGS's Income in the fourth quarter 2024


ORGS Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q4 MRQ) 194.31 % 155.5 % 43.36 % -0.27 %
Sequential Operating Income Change (Q4 MRQ) 116.75 % -35.64 % -22.05 % -8.98 %
Y / Y Operating Income Growth (Q4 TTM) -25.86 % 18.81 % 19.61 % 9.24 %
Sequential Operating Income Growth (Q4 TTM) 43.28 % 15.12 % 7.78 % -0.22 %
Operating Income 5 Year Avg. Change 10.08 % 0.14 % -0.95 % 9.03 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q4 MRQ) 207.66 % - -97.24 % 22.99 %
Sequential Income from Cont. Ops. Change (Q4 MRQ) 119.9 % - -95.98 % 8.13 %
Y / Y Income from Cont. Ops. Change (Q4 TTM) -24.5 % 3.72 % 9.35 % 11.58 %
Sequential Income from Cont. Ops. Change (Q4 TTM) 39 % -3.53 % -5.92 % 4.61 %
Income from Cont. Ops. 5 Year Avg. Change 13.48 % -18.64 % -17.89 % 8.38 %

ORGS Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q4 MRQ) 207.66 % 128.53 % 37.76 % 25.85 %
Q / Q Net Income Growth (Q4 MRQ) 119.9 % 19.99 % -20.76 % 7.59 %
Y / Y Net Income Change (Q4 TTM) -24.5 % -18.88 % -9.02 % 9.66 %
Sequential Net Income Change (Q4 TTM) 39 % -3.09 % -6.02 % 5.18 %
Net Income 5 Year Avg. Growth 13.48 % 14.54 % 6.23 % 9.5 %

ORGS's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q4 MRQ) - - -97.24 % 22.99 %
Sequential EPS from Cont. Ops. Change (Q4 MRQ) - - -95.98 % 8.13 %
Y / Y EPS from Cont. Ops. Change (Q4 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q4 TTM) - - - 33 %
EPS from Cont. Ops. 5 Year Avg. Growth 45.24 % -29.48 % -17.89 % 8.38 %



ORGS EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q4 MRQ) - 90.85 % 37.76 % 8.38 %
Q / Q EPS Net Growth (Q4 MRQ) - 30.6 % -20.76 % 7.59 %
Y / Y EPS Net Change (for 12 months ending Q4 TTM) - - - 92.65 %
Sequential EPS Net Change (for 12 months ending Q4 TTM) - - - 33 %
EPS Net 5 Year Avg. Change - 14.54 % 6.23 % 9.5 %



Orgenesis Inc reported bottom-line of $ -4.84 in the fourth quarter, compare to $ -0.23 in the same quarter a year ago. Major Pharmaceutical Preparations industry grew by 90.85%, while Healthcare sector increased by 37.76%, and overall market improved by 25.85%.

Sequentially company's EPS fell by -13.26% from the third quarter results. . Looking into annual growth, income per share grew by -68.27% on average in last five years, while S & P 500's including only Businesses with the fourth quarter 2024 reports, average yearly income per share growth is 9.5%.

ORGS Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q4 MRQ) - 56.99 % 49.29 % 32.85 %
Sequential Free Cash Flow Change (Q4 MRQ) - -24.26 % -6.05 % 113.08 %
Y / Y Free Cash Flow Change (Q4 TTM) - 96.5 % 72.27 % 10.44 %
Sequential Free Cash Flow Change (Q4 TTM) - 80.96 % 57.27 % 9.43 %
Free Cash Flow 5 Year Avg. Change - 9.48 % 6.35 % 10.83 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q4 MRQ) - -82.47 % - -81.15 %
Sequential Net Cash Flow Change (Q4 MRQ) - - - -
Y / Y Net Cash Flow Change (Q4 TTM) - 198.68 % 173.42 % -
Sequential Net Cash Flow Change (Q4 TTM) - 15908 % - -
Net Cash Flow 5 Year Avg. Change - -8.21 % -1.7 % -32.35 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q4 MRQ) - 3.32 % 11.12 % 22.34 %
Sequential Capital Expenditures Change (Q4 MRQ) - 26.08 % 20.75 % 17.09 %
Y / Y Capital Expenditures Change (Q4 TTM) -87.45 % 24.06 % 16.17 % 41.57 %
Sequential Capital Expenditures Change (Q4 TTM) 0 % 20.81 % 14.03 % 6.83 %
Capital Expenditures 5 Year Avg. Change - 10.99 % 9.09 % 10.7 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 







Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.